secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHEMED CORP (CHE)
CIK:        0000019584
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001562762-24-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemed Q4 revenue up 7.2% to $585.9M; VITAS adjusted EBITDA +61.6%; FY2024 guidance issued
--------------------------------------------------------------------------------

- GAAP diluted EPS $5.90 (+42.9% YoY); adjusted diluted EPS $6.60 (+35.0% YoY).
- VITAS net patient revenue $350M (+13.6%), ADC 19,352 (+11%), adjusted EBITDA excl. Medicare Cap $83.3M (+61.6%), margin 23.7%.
- Roto-Rooter revenue $235.9M (-1.1%), adjusted EBITDA $64.9M (-6.4%), margin 27.5% (down 154 bps).
- FY2024 adj. EPS guidance $23.30-$23.70 vs 2023 adj. EPS $20.30; VITAS rev growth 9-9.8%, Roto-Rooter rev growth 3.5-4%.
- Cash $264M, no debt; repurchased 79,512 shares for $46M at $579.09 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/19584/000156276224000036/0001562762-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/19584/000156276224000036/che-20240227x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer